Methods	Single centre RCT. Study duration: 2001 to 2003.
Participants	Low-risk GTN. Number randomised: 46. Number evaluable:46. Randomisation ratio of 1.5 MTX:1 DACT applied due to economic limitations
Interventions	Group1: MTX, IM, 30mg/m2 repeated every week. Group2: ACT, IV, 1.25mg/m2 repeated every 2 weeks.
Outcomes	Efficacy: remission rate, number of cycles to remission, duration of treatment, need for second-line chemotherapy Adverse effects: nausea.
Notes	Risk scoring: WHO/FIGO 2000. Non-response defined as < 10% decrease in hCG over 3 weeks, more than 20% rise in hCG over 2 consecutive weeks or the appearance of new metastatic disease Remission defined as hCG < 5 IU/L. One additional cycle was given after remission
Risk of bias
Bias	Authors’ judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Sequence generation not reported.
Allocation concealment (selection bias)	Unclear risk	Allocation concealment not reported.
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Blinding not reported.
Incomplete outcome data (attrition bias) All outcomes	Low risk	100% of participants analysed.
Selective reporting (reporting bias)	Low risk	All pre-specified outcomes reported. Toxicity not reported in detail but said to be ‘minimal’ in both groups
Other bias	Unclear risk	This trial has the same authors, location and protocol as Yarandi 2008, with consecutive enrolment dates, yet the later Yarandi 2008 study does not refer to Gilani 2005. It is not clear why. Attempts to clarify this with Dr Yarandi have been unsuccessful